| Symbol | GNFTY |
|---|---|
| Name | GENFIT S.A. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | |
| Telephone | 33 3 20 16 4000 |
| Fax | — |
| — | |
| Website | https://www.genfit.com |
| Incorporation | FR |
| Incorporated On | 1999 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | Ernst & Young LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001757064 |
| Description | Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The companys research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. Additional info from NASDAQ: |
No news found.